Prime Medicine is a biotech firm developing one-time genetic therapies using its Prime Editor platform, which precisely rewrites DNA to treat diseases.
No revenue yet; the company is pre-commercial, with annual net losses around USD 0.20B, funded by investors rather than product sales.
Its Prime Editor technology is a novel gene-editing approach, but competitors like CRISPR Therapeutics and Editas Medicine are advancing similar tools, and the lack of approved products leaves the moat unproven.
Key events, in time order
None yet
None yet
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
